Organovo Holdings, Inc. Announces Management Changes
September 17, 2020 at 08:07 am EDT
Share
The Board of Organovo Holdings, Inc. appointed Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous to the Board, with the appointments effective upon the final adjournment of the 2020 Annual Meeting. Ms. Milhous was appointed as a Class I director to hold office until the 2021 Annual Meeting of Stockholders and Messrs. Cohen and Gobel were appointed as Class II directors to hold office until the 2022 Annual Meeting. Douglas Jay Cohen has served as president and Chief Executive Officer of IR Medtek LLC since January 2019. David Gobel has served as Chief Executive Officer of Methuselah Fund LLC since December 2016. Alison Tjosvold Milhous is currently an independent consultant assisting public and private companies with accounting and reporting needs primarily within the life sciences and technology industries. The Board approved the appointment Adam Stern as member of Audit and Compensation Committees. The company appointed Douglas Jay Cohen as member of Audit and Compensation Committees and Chair of Nominating and Corporate Governance Committee. The company appointed David Gobel as Chair of Compensation Committee and member of Nominating and Corporate Governance Committee. The company appointed Alison Tjosvold Milhous as Chair of Audit Committee and member of Nominating and Corporate Governance Committee. On September 15, 2020, the Board appointed Mr. Murphy as the company’s Executive Chairman and Principal Executive Officer. Mr. Murphy re-joined the company’s Board in July 2020. On September 15, 2020, the Board also appointed Chris Heberlig as President and Principal Financial Officer of the company. Mr. Heberlig currently serves as a financial consultant focused on the life sciences industry, most recently serving at Danforth Advisors LLC since September 2020 and at 2C Advisory LLC since June 2020. On September 15, 2020, the Board also appointed Jeffrey N. Miner as Chief Scientific Officer of the Company. Jeff currently serves as co-founder and Chief Scientific Officer for Viscient. On September 15, 2020, the Board also appointed Thomas Einar Jurgensen as General Counsel of the Company. Mr. Jurgensen is currently in private practice with Optima Law Group. In accordance with the terms of the Cooperation Agreement, Carolyn Beaver, Taylor Crouch, Mark Kessel and Kirk Malloy, Ph.D. each resigned as directors, effective immediately following the final adjournment of the 2020 Annual Meeting and the appointment of Ms. Milhous and Messrs. Cohen and Gobel to the Board.
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
ORGANOVO HOLDINGS, INC. 
